Our previous studies have identified that the bone marrow (BM) derived Bregs presented with phenotype CD19+CD24hiCD38hi conferring an immunosuppressive BM microenvironment in MM and their proportions within CD19+ B cells were correlated with treatment efficacy and prognosis.15 Here, CD19 is linked to Miyoshi myopathy.